Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coagulation abnormalities in malignancy: a review.

R L Bick1

  • 1Department of Medicine, University of California, Los Angeles.

Seminars in Thrombosis and Hemostasis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contaminants in heparins continue to be unfolded.

International angiology : a journal of the International Union of Angiology·2008
Same author

The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.

Clinical hemorheology and microcirculation·2007
Same author

Antiphospholipid thrombosis syndromes.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2001
Same author

Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.

Drugs·2000
Same author

An update on heparins at the beginning of the new millennium.

Seminars in thrombosis and hemostasis·2000
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Cancer patients frequently experience hemostasis alterations, leading to hemorrhage or thrombosis. Understanding these complex hemostatic defects is crucial for effective diagnosis and treatment in malignancy care.

Area of Science:

  • Oncology
  • Hematology
  • Hemostasis

Background:

  • Patients with cancer often exhibit multifaceted hemostasis alterations.
  • Hemorrhage or thrombosis is a frequent fatal event in advanced malignancies.
  • Increased survival in cancer care leads to more frequent hemostatic complications.

Purpose of the Study:

  • To review the complex hemostatic alterations in cancer patients.
  • To emphasize the need for a logical diagnostic and therapeutic approach.
  • To highlight common hemostatic defects like thrombocytopenia and DIC.

Main Methods:

  • Review of existing literature on hemostasis in malignancy.
  • Discussion of diagnostic challenges and therapeutic strategies.
  • Analysis of hemorrhage and thrombosis as common complications.

Related Experiment Videos

Main Results:

  • Thrombocytopenia is the most common cause of hemorrhage in cancer.
  • Disseminated Intravascular Coagulation (DIC) frequently causes hemorrhage or thrombosis.
  • Antineoplastic drugs and radiation therapy can exacerbate bleeding.

Conclusions:

  • Hemostatic defects in cancer patients require careful diagnosis and management.
  • A sequential and logical approach is essential for effective therapy.
  • Recognizing and treating hemostasis alterations improves patient outcomes.